Cardiac allograft vasculopathy (CAV) is the leading cause of late morbidity and mortality in heart transplant recipients, accounting for one-third of all-cause mortality at 5 years [ 1 x [1] Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., Dipchand, A.I., Benden, C., Christie, J.D. et al. International society for heart and lung transplantation, the registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J. Heart Lung Transplant. 2013; 32: 951–964 Abstract | Full Text | Full Text PDF | PubMed | Scopus (281) | Google Scholar See all References ] [1] . The pathophysiology of CAV is closely linked to both immunologic factors, such as alloreactive T-cell and antibody activation, and non-immunologic factors, including pre-transplant coronary artery disease, cytomegalovirus (CMV) infection, older age of the donor and recipient, recipient's conventional risk factor (e.g. hyperlipidemia, hypertension and diabetes mellitus) and ischemia/reperfusion injury [ 2 x [2] Rahmani, M., Cruz, R.P., Granville, D.J., and McManus, B.M. Allograft vasculopathy versus atherosclerosis. Circ. Res. 2006; 99: 801–815 Crossref | PubMed | Scopus (219) | Google Scholar See all References ] [2] . This complex etiology makes it difficult to prevent and suppress the development of CAV.